Latest Ipilimumab Stories
MOUNTAIN VIEW, California, February 25 /PRNewswire/ -- BN ImmunoTherapeutics, Inc. announced today that the first detailed data on PROSTVAC(TM) since the vaccine was licensed from the National Institutes of Health (NIH) is now available.
PRINCETON, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today the allowance of an investigational new drug (IND) application filed with the U.S.
Ipilimumab Will Earn Decision Resources' Clinical Gold Standard for Stage IV Malignant Melanoma in 2012, According to a New Report from Decision Resources WALTHAM, Mass., Jan.
PRINCETON, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today provided an overview of the company's strong science-base and strategy for maximizing the value of its product portfolio.
Medarex, a biopharmaceutical company, and The Massachusetts Biologic Laboratories of the University of Massachusetts Medical School have announced that a Phase II trial of an anti-C difficile antibody combination treatment in patients with C difficile associated diarrhea successfully met its primary objective.
PRINCETON, N.J. and JAMAICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Medarex, Inc. and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti-C.
Poniard Pharmaceuticals, a biopharmaceutical company focused on oncology, has announced positive incremental data from its ongoing Phase II clinical trial of picoplatin in combination with docetaxel and prednisone as first-line therapy for metastatic hormone-refractory prostate cancer.
Bristol-Myers Squibb Company and Medarex have announced updated survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma who had previously been treated.
Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) today announced updated survival data from three Phase 2 studies of ipilimumab in patients with advanced metastatic melanoma (Stage III or IV) who had previously been treated.
OSLO, August 28 /PRNewswire-FirstCall/ -- - Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC) Algeta ASA , the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain palliation study was met.
- an ornament or knob in the shape of a flower